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bstract
New polymeric composite materials containing a nanohybrid to be used for the controlled release of an antibiotic molecule, chloramphenicol
uccinate, have been formulated, prepared and characterised. The nanohybrid consists of a layered double hydroxide of Mg–Al hydrotalcite-
ype, in which the nitrate anions present in the host galleries were replaced with chloramphenicol succinate anions (CFS−) by a simple
on-exchange reaction. Different amounts of the hybrid material were incorporated in polycaprolactone and processed as films of 0.15 mm
hickness. The composite materials were analysed by X-ray diffractometry and thermogravimetry and their mechanical properties were
etermined. They showed properties even better than those of the pristine polymer. The release process of the antibiotic molecules was found
o be very interesting and promising for tuneable drug delivery. It consists of two stages: an initial stage of a very rapid burst, in which a small
raction of drug is released; and a second stage that is much slower, extending for a longer and longer time. This behaviour is profoundly
ifferent and much slower than that of a sample in which the antibiotic molecule is directly incorporated into the polymeric matrix. The
arameters influencing drug release have been individuated and discussed.
2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
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. Introduction
Delivery of drugs by new technologies is a highly topical
hallenge of polymer chemistry. So far, numerous products
ither on the market or in development are being pro-
uced and studied to obtain precise and tuneable control
f molecular release. These controlled release drug delivery
echnologies have not only revitalised old pharmaceuticals
ut have also been directed toward newer biopharmaceuticals
roduced by genetic research [1–4].
∗ Corresponding author. Tel.: +39 0871 355 4095; fax: +39 0871 355 4095.
E-mail addresses: tete@unich.it (S. Tete`),
libertomastrangelo@hotmail.com (F. Mastrangelo).
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Polymers have played a major role in the development
f controlled release systems; as matter of a fact, the early
olymeric drug delivery systems incorporated commercially
vailable polymers [5–8]. Successively extensive research
fforts aimed to improve both the polymers and the processes,
s well as to apply them to the controlled release of a wide
ariety of pharmaceuticals or more general ‘active’ products.
owever, with the continued development of controlled-
elease technology, the need has arisen for materials with
ore specific drug delivery properties [9–12]. These materi-
ls include new biodegradable polymers, polymers with both
ydrophilic and hydrophobic characteristics, and hydrogels
hat respond to temperature or pH variations. In addition,
ethods to overcome some of the barriers associated with
urrent drug delivery are necessary. The possibility of reduc-
of Chemotherapy. All rights reserved.
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ng, or even eliminating, oral administration of possibly
angerous drugs (such as anti-inflammatories, antibiotics,
tc.) using new biocompatible polymers in which drugs are
irectly incorporated is currently under investigation. In the
edical field, in particular in surgery, it may be of great clin-
cal utility to be able to modulate the activation of tissue
epair and the regeneration processes, which are at the base
f the healing process. In this context, some surgical devices
e.g. sutures, membranes, osteosynthesis plaques) made of
eabsorbable materials able to favour the completion of the
arious reparatory phases and that do not necessitate further
urgical intervention for their removal are extremely useful.
t is an advantage to load these devices with active pharma-
ological substances. In fact, the possibility of local diffusion
f a drug through biocompatible and reabsorbable matrixes
ffers the advantage of a drastic reduction of the system-
cally administered dose and, as a consequence, of related
ide effects. A limit of these systems is the reduced capac-
ty of guaranteeing an adequate and slow local release of the
rug. A more remarkable innovation in this field is currently
oming from nanoscience and nanotechnologies, which are
pening new opportunities for producing materials with sur-
risingly unusual properties. The possibility of manipulating
t atomic or molecular level induces structures with unique
haracteristics and completely new functionalities to be used
ot only as structural materials but also as smart structures
or many fields such as drug delivery. Innovative compos-
tes can be obtained by employing a suitable nanoscale or
ther fine-scale architecture to control the structural organ-
sation and, as a consequence, the physical and mechanical
roperties of the material [13]. Nanoscale reinforcement has
ound widespread interest in the macromolecular field, since
olymer properties are remarkably improved compared with
irgin polymer or conventional microcomposites. On the
ther hand, a wide range of additives, including biologically
ctive molecules, can be immobilised on the inorganic lamel-
ae with ionic bonds. They can be successively released by
xchange reactions with ions present in the solutions they
re put in contact with. Recently, a novel therapeutic deliv-
ry system based on magnesium–aluminium-layered double
ydroxides (LDHs) was proposed [14]. LDHs consist of lay-
rs of magnesium hydroxide, with aluminium isomorphically
ubstituted to give the layers a net positive charge. This charge
s balanced by interlayer hydrated anions, resulting in a multi-
ayer of alternating host layers and gallery ions [15]. Using an
on-exchange reaction, many novel complexes may be syn-
hesised, and indeed anti-inflammatories, antibiotics, plant
rowth regulators and others have been incorporated into
DHs, obtaining nanohybrids that can slowly release the
ctive molecules [16,17]. We incorporated these nanohybrids
ontaining an anti-inflammatory molecule into a biodegrad-
ble polycaprolactone and obtained a much slower release
han with the molecule directly incorporated into the polymer
18].
In the present paper, we present the preparation, structural
nd physical characterisation, and drug release profiles of
s
w
ctimicrobial Agents 29 (2007) 417–423
ew nanohybrid composites, obtained by fixing an antibiotic
rug, chloramphenicol succinate (CFS) (4-[2-(2,2-dich-
oroacetyl)amino-3-hydroxy-3-(4-nitrophenyl)-propoxy]-4-
xo-butanoic acid), with ionic bonds into a lamellar inorganic
ompound and incorporating the obtained hybrid material
nto a polymeric matrix, polycaprolactone. Previous papers
ave reported the intercalation of an anti-inflammatory
rug into HTlc, via an ion-exchange procedure, obtain-
ng nanohybrids with high drug loading [19,20], or by
econstruction or co-precipitation methods [21] obtaining
ompounds with low loading. In our case, a high-loading
Tlc–CFS complex has been prepared and dispersed into the
iodegradable polymer to obtain systems characterised by
xcellent mechanical properties and very slow drug release.
he polymeric matrix is a polyester, polycaprolactone,
hich has the advantage of adding biodegradability and
iocompatibility to the traditional properties and therefore
an be tailored for biomedical applications in many fields
22–24].
This paper is a part of a wider investigation aimed at corre-
ating the active molecule loading, the thickness of the sample
nd the processing conditions with the release behaviour. A
omplete picture of the interrelationship between the dif-
erent parameters will allow the samples to be tailored for
pecific applications.
. Materials and methods
.1. Materials
A well crystallised and characterised Mg–Al hydrotalcite-
ike compound with the formula [Mg0.65Al0.35(OH)2]
CFS)0.26(NO3)0.09 × 1 H2O (hereafter referred to as
Tlc–CFS) was obtained by NO3−/chloramphenicol succi-
ate anion (CFS–) exchange reaction as previously reported
18].
Poly(-caprolactone) (PCL) (Mn = 80 000 Da), chloram-
henicol succinate sodium salt (CFS-Na) and tetrahydrofuran
THF) were used as received from the manufacturer (Sigma-
ldrich, Milan, Italy).
.2. Preparation of the nanohybrid
.2.1. Preparation of composites by solvent casting of
Tlc–CFS and PCL solution
A THF suspension (30 mL) containing 100 mg of
Tlc–CFS was stirred for 3 h at room temperature. Then, 1 g
f high-molecular-weight PCL was added and the mixture
as stirred for 3 h at room temperature. The solvent was then
lowly evaporated in a Petri dish, obtaining a PCL sample
ith 10% HTlc–CFS. Using the same procedure, two moreamples were obtained, containing 5% and 20% HTlc–CFS.
Hereafter, the samples will be named as PCL–HCFSn,
here n is the amount of HTlc–CFS present in the
omposite.
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Fig. 1. Thermogravimetric analysis (thermograms) of (a) PCL; (b)
HTlc–CFS; (c) PCL–HCFS5; (d) PCL–HCFS10; and (e) PCL–HCFS20,
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hybrid weight. In Table 1 we report the amount of CFS in
each sample.
Table 1
Concentration of the hybrid HTlc–CFS, concentration of the antibiotic
molecule CFS and the theoretical quantity of drug that can be released (mgt
CFS) for all the samples
Sample % HTlc-CFS % CFS mgt CFS
PCL–HCFS5 5 2.85 0.97L. Tammaro et al. / International Journ
.2.2. Preparation of composite by solvent casting of
FS-Na and PCL solution
A THF suspension (30 mL) of 60 mg CFS-Na was stirred
or 3 h at room temperature. Then, 1 g of high-molecular-
eight PCL was added and the mixture was stirred for a
urther 3 h at room temperature. The solvent was then slowly
vaporated in a Petri dish.
Hereafter, the sample will be referred to as PCL–CFSNa6.
.3. Film preparation
Films were obtained by moulding the previous samples,
ried in vacuo, in a Carver Laboratory Press between two
eflon sheets at a temperature of 70 ◦C and rapidly quenching
hem in an ice water-bath. No cracks or imperfections were
isible on the surface of the films, implying that incorporation
f the nanohybrid did not interfere with the formation of
omogeneous films.
.4. Methods of investigation
Thermogravimetric analysis (TGA) was carried out in an
ir atmosphere with a Mettler TC-10 thermobalance from
oom temperature to 800 ◦C at a heating rate of 20 ◦C/min.
egradation temperatures, Td, are evaluated as the midpoint
f the degradation step.
X-ray powder diffraction measurements were performed
ith a Bruker diffractometer (equipped with a continuous
can attachment and a proportional counter) with Ni-filtered
u K radiation (λ = 1.54050 A˚).
The mechanical properties of the samples were evaluated
rom the stress–strain curves obtained using a dynamo-
etric apparatus INSTRON 4301. The experiments were
onducted at room temperature with a deformation rate of
mm/min. Dumbbell-shaped samples with initial length of
0 mm, width of 5 mm and thickness of 150m were inves-
igated. Elastic moduli were derived from the linear part of
he stress–strain curves, giving to the sample a deformation
f 0.1%.
Ultraviolet (UV) spectroscopy, set at a wavelength of
= 278 nm, was used to quantify the amount of CFS released
nto the solution in each time interval. A calibration curve
as used to determine the molar extinction coefficient in the
nvestigated concentration range. Measurements were made
n triplicate and the values were averaged. A circular sample
f each PCL–HCFSn sample, with a surface of 1 cm diam-
ter, was cut from the film of thickness 150m and placed
nto 100 mL of physiological saline solution at room tem-
erature and kept in the dark. After specific intervals, 1 mL
f solution was removed and replaced with 1 mL of fresh
olution to maintain a constant volume of release medium.
o hydrolytic degradation of PCL occurred in the timehat the release measurements were performed and therefore
he active molecule release is not due to polymer degrada-
ion and erosion but only to diffusive movement into the
atrix.
P
P
P
Chere the number represents the amount of HTlc–CFS present in the com-
osite. Heating rate 20 ◦C/min in air flow. PCL, poly(-caprolactone).
. Results
.1. Thermogravimetric analysis
All the samples were analysed by TGA to determine the
egradation temperatures and to confirm the content of the
norganic component in the nanohybrid materials after ther-
al decomposition of the organic part in air up to 800 ◦C
21].
Fig. 1 shows the TGA curves of the samples. The ther-
ogravimetric curve of PCL (Fig. 1a) displays one main
egradation step with a Td midpoint value of 402 ◦C. It can
e seen that the shapes of the curves are very similar for
oth neat PCL and the composites, although the degradation
emperatures for the samples PCL–HCFS5, PCL–HCFS10,
CL–HCFS20 are 44 ◦C, 47 ◦C and 40 ◦C lower, respectively,
han that of pure PCL. This behaviour is due to the presence
f nanohybrid HTlc–CFS in the samples, which degrade at
lower temperature than PCL. The Td midpoint value of
Tlc–CFS is 374 ◦C.
Considering the stoichiometric relations between HTlc
nd CFS in the formula: [Mg0.65Al0.35(OH)2](CFS)0.26
NO3)0.09 × 1 H2O, the amount of CFS is 57.0% of the totalCL–HCFS10 10 5.70 2.05
CL–HCFS20 20 11.40 5.05
CL–CFSNa6 0 6 2.55
FS, chloramphenicol succinate.
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Fig. 2. X-ray diffractograms of (a) HTlc-NO3; (b) HTlc–CFS; (c)
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Fig. 3. Stress–strain plots of (a) PCL; (b) PCL–HCFS5; (c) PCL–HCFS10;
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σCL–HCFS5; (d) PCL–HCFS10; and (e) PCL–HCFS20, where the num-
er represents the amount of HTlc–CFS present in the composite. PCL,
oly(-caprolactone).
.2. X-ray powder diffraction measurements
X-ray analysis was used to study the effect of the inter-
alation of CFS into the interlayer region of HTlc and to
nvestigate the dispersion degree of the nanohybrid into the
olymer.
Fig. 2 shows, in the 2–30 ◦C interval of 2θ, the X-ray
iffractograms of the pristine hydrotalcite in the nitrate form,
Tlc-NO3 (Fig. 2a), the nanohybrid HTlc–CFS (Fig. 2b)
nd the composites PCL–HCFS5, PCL–HCFS10 and PCL-
CFS20 (Fig. 2c–e). The X-ray diffractogram of the starting
Tlc-NO3 (Fig. 2a) shows an intense peak at 2θ = 10.2◦,
hich corresponds to the 003 basal plane of 0.87 nm.
xchange of nitrate ions with the organic anion of the drug
FS gives rise to expansion of the d-spacing. We observe
hat the first peak of HTlc–CFS is located at 2θ = 3.57◦,
orresponding to a basal spacing of 2.47 nm. This increase
ccounts for the intercalation of CFS anions that have sub-
tituted the nitrate anions inside the galleries. The second
nd third peaks of HTlc–CFS (Fig. 2b) correspond to the
igher harmonics of the interlayer distance. All the peaks
re sharp, indicating an ordered accommodation of the drug
nions within the interlayer regions.
The pattern of the composites PCL–HCFS5 (Fig. 2c),
CL–HCFS10 (Fig. 2d) and PCL–HCFS20 (Fig. 2e) shows
hat the HTlc–CFS is present in the polymer in a much less
rdered arrangement. Indeed, PCL–HCFS5 (Fig. 2c) and
h
i
able 2
echanical properties evaluated from the stress–strain curves for all samples
ample σy (MPa) εy (%)
CL 4.858 9.818
CL–HCFS5 8.757 9.825
CL–HCFS10 10.065 13.521
CL–HCFS20 9.648 9.918
y, stress at the yield point; εy, deformation at the yield point; σb, stress at the breaknd (d) PCL–HCFS20, where the number represents the amount of
Tlc–CFS present in the composite. PCL, poly(-caprolactone).
CL–HCFS20 (Fig. 2e) show very broad peaks of the inor-
anic component at 2 values of ca. 3.5◦, 7.0◦ and 10.4◦,
hereas PCL–HCFS10 (Fig. 2d) does not show any peak,
ndicating a possible exfoliation of the inorganic lamellae.
The PCL of the composites is crystalline and shows the
sual peaks of its structure at 2θ = 21.3◦ and 23.7◦, although
f different intensity [25].
.3. Mechanical properties
In Fig. 3 we show the engineering stress–strain curves
or PCL (Fig. 3a), PCL–HCFS5 (Fig. 3b), PCL–HCFS10
Fig. 3c) and PCL–HCFS20 (Fig. 3d). The drawing curve of
ample PCL (Fig. 3a) is conventional, with upper and lower
ield points describing the neck formation and subsequent
ransformation into an oriented structure. The neck propa-
ation, after the yield drop, ends before 300%; afterwards,
steeper increase of the stress and the breaking point at ca.
00% are observable. The composites samples (Fig. 3b–d)
how a much more pronounced and sharper yield and
ost-yield drop than the initial sample. Fracture of the com-
osite materials occurs at higher deformation than the pure
olymer.
An improvement of all the mechanical parameters can be
bserved (see Table 2).As matter of fact, all the composites show a consistently
igher elastic modulus in addition to a higher yield and break-
ng stress.
σb (MPa) εb (%) Elastic modulus (MPa)
10.085 607.7 220
13.834 609.2 305
14.789 656.2 315
16.482 659.7 390
ing point; εb, deformation at the breaking point; PCL, poly(ε-caprolactone).
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cal saline solution.
.4. Chloramphenicol succinate release
The calibration curve of CFS in physiological saline solu-
ion is shown in Fig. 4. The UV absorbance at λ = 278 nm is
eported as a function of CFS concentration (mg/10 mL) in
he range of interest for release from the polymeric matrix. We
an observe that the dependence of the absorbance on the con-
entration is linear in the investigated range, and only at the
ighest concentration was a slightly lower value measured,
ndicating an initial deviation from linearity.
The release of CFS from PCL–HCFS5, PCL–HCFS10 and
CL–HCFS20 is presented in Fig. 5. It is worth recalling
hat the CFS content is 57.0% of the total HTlc–CFS, and
herefore the samples contain 2.85%, 5.70% and 11.4% of
rug, respectively (see Table 1). Depending on the sample
eight, the theoretical quantity of drug that can be released
s also reported in Table 1.
In Fig. 5, the sample with CFS directly dispersed into theolymer (PCL–CFSNa6), with a concentration of 6%, is also
ompared with PCL–HCFS10.
ig. 5. Ultraviolet (UV) absorbance at λ = 278 nm, reported as a function
f time (min) for samples PCL–CFSNa6 and PCL–HCFS5, PCL–HCFS10
nd PCL–HCFS20, where the number represents the amount of HTlc–CFS
resent in the composite.
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tig. 6. Time for complete release of chloramphenicol succinate (CFS)
eported as a function of concentration.
We observe that the three samples containing the CFS
rug in the nanohybrid show the same qualitative release
ehaviour. The typical time-dependent profile of each sample
hows fast release in the early period, followed by a reduced
elease. The first stage lasts ca. 100 min and is completed in
n increasing time with increased drug loading in the sample.
n the sample with the highest drug concentration (11.4%),
he first stage extends up to 200 min, whereas ca. 100 min are
eeded for the sample with the lowest concentration of CFS
2.85%). In the second stage, after the rapid burst of a frac-
ion of CFS, drug release increases linearly with time, with
he slope increasing with the increase in drug concentration
see Fig. 5), as already reported in the case of diclofenac [18].
The release behaviour of sample PCL–CFSNa6, contain-
ng the drug directly incorporated into the polymeric matrix,
s very different. It is linear with time up to 100 min and after-
ards reaches the value corresponding to complete release of
he incorporated quantity (see Table 1). The drug is quickly
eleased, with linear kinetics with time, and reaches the
quilibrium value after 250 min. The corresponding sample,
CL–HCFS10, containing approximately the same quantity
f drug anchored to the HTlc layers, has released only 30%
f the theoretical quantity after 250 min. Assuming a linear
elease with time, up to complete drug release, we can cal-
ulate the time needed for complete release in each sample
ontaining the drug anchored in the nanohybrid. In Fig. 6,
e report the time needed for complete release as a func-
ion of the concentration of CFS. We observe that the total
elease time is linearly dependent on the nanohybrid loaded
n the polymer, and it is much higher than the time needed
or complete release of the drug directly incorporated into the
olymer, represented by the star in Fig. 6.
It is worth noting that the different dispersion of the
norganic sample, in terms of distortion of the structure or
elamination, as shown by the X-rays, appears not to have
strong influence on the release time. Indeed, Fig. 6 shows
good linear correlation, in spite of different dispersion of
he inorganic lamellae in the different samples. The release is
trongly dependent on the ionic force of the outside solution,
he diffusion of anions inside and outside the sample fol-
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owing water diffusion, and the sample thickness. All these
arameters must be investigated in further studies to derive a
omplete picture of the release behaviour. This will allow the
arameters to be changed, obtaining tuneable drug delivery.
. Discussion and conclusions
We have formulated, prepared and characterised new
olymeric composite materials containing a nanohybrid to
e used for controlled molecular delivery of an antibi-
tic molecule, CFS [1–4]. Different amounts of the hybrid
aterial were incorporated in PCL, a biocompatible and
iodegradable polyester mainly applied in biomedical appli-
ations [22–24,26].
The mechanical properties of the composite material were
nvestigated and showed that the samples display very good
roperties, better than the pure polymer. However, the most
nteresting property for biomedical topical applications is
he release behaviour. As a matter of fact, in our films the
elease of antibiotic molecules, anchored on the lamellae of
n inorganic compound, was found to be very interesting and
romising for tuneable drug delivery.
Release consists of two stages: (i) an initial very rapid
urst, for which the time to be completed is dependent on
he hybrid concentration in the polymeric matrix; and (ii)
second stage that is much slower, extending for a longer
nd longer time, also depending on the hybrid concentra-
ion. We suggest that the first stage is due to exchange of
FS ions anchored to the inorganic lamellae on the surface
f the sample. Therefore, the amount of antibiotic molecules
nd the time to complete this stage can be varied by vary-
ng the composition, the ionic force of the outside solution,
nd the surface area. At variance, the CFS anions anchored
o the inorganic lamellae inside the film are released from
he sample in the second stage. They can be removed not
nly by exchange reactions but also by diffusion of anions
nd counter-anions that must be exchanged. Moreover, the
raction of drug released in the first burst from the surface
epends on the sample thickness, which determines a differ-
nt surface/volume ratio. In this paper, we used a thickness of
50m and a comparison with different values is in progress.
n conclusion, the release can be tuned in many ways (as
onic force of the outside solution, concentration of the drug
nside the inorganic lamellae, concentration of the inorganic
omponent into the polymeric matrix, thickness and form
f the sample, type of polymeric matrix) in order to obtain
he best results for different local applications. Indeed, con-
rol of the flogistic mediators involved in tissue reparation of
he oral cavity is able to improve both the recovery and the
ost-operative course. Employment of pharmacologically-
oaded delivery systems allows a reduction or avoidance of
ystemic delivery of antibiotics, anti-inflammatory drugs and
ain killers [27,28]. Moreover, by reducing the systemic con-
entration of the drugs, it is possible to limit their side effects.
his is especially helpful in the case of patients with con-
[timicrobial Agents 29 (2007) 417–423
omitant diabetes, hepatopathy, nephropathy, cardiopathy or
aemorrhagic diathesis.
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